NCT06006624 is a Phase 4 clinical trial of Exparel 30 mL in ACL, sponsored by Rothman Institute Orthopaedics.

Who is sponsoring NCT06006624?

NCT06006624 is sponsored by Rothman Institute Orthopaedics.

What drugs are being tested in NCT06006624?

Interventions in NCT06006624: Exparel 30 mL, 0.5% bupivacaine, Dexamethasone, iPACK block.

What condition does NCT06006624 study?

NCT06006624 studies ACL, Postoperative Pain.

Is NCT06006624 still recruiting?

NCT06006624 is currently enrolling by invitation. Last updated 21 June 2024.

Last reviewed 2024-06-21 · How we verify

NCT06006624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exparel vs Block for ACL Reconstruction

ENROLLING BY INVITATION Phase 4 Last updated 21 June 2024

What this trial tests

Phase 4 trial testing Exparel 30 mL in ACL in 154 participants. Enrolling by invitation.

Timeline

21 August 2023

Primary endpoint
30 October 2024

30 October 2024

Quick facts

Lead sponsor	Rothman Institute Orthopaedics
Phase	Phase 4
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	154
Start date	21 August 2023
Primary completion	30 October 2024
Estimated completion	30 October 2024
Sites	1 location across United States

Drugs / interventions tested

Exparel 30 mL — full drug profile →
0.5% bupivacaine — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
iPACK block — full drug profile →

Conditions studied

ACL — all drugs for ACL →
Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

Rothman Institute Orthopaedics

Who can join

18 and older, any sex, with ACL or Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become U.S. Food and Drug Administration (FDA) approved for use in interscalene brachial plexus nerve blockade as well as infiltrative blockade. Delivery in this form is reported to provide up to 72 hours of extended-release bupivacaine. Exparel's use as a regional anesthetic has also become increasingly common and has shown promise when utilized in Anterior Cruciate Ligament (ACL) reconstruction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Regional Anesthesia Utilizing Liposomal Bupivacaine, With or Without Dexamethasone, Provides Excellent Pain Control and Minimizes Opioid Consumption Following Anterior Cruciate Ligament Reconstruction.
Johns WL, Voskeridjian A, Miltenberg B, Muchintala R, et al · · 2026 · PMID 41522461 · DOI 10.1177/23259671251401596

Verify or expand the search:

Other recruiting trials for ACL

Currently open trials in the same condition.

NCT06529679 — Michigan Split-belt Treadmill Training Program to Improve Acute Knee Biomechanics After ACL Reconstruction · NA · recruiting
NCT06194682 — Anterior Cruciate Ligament Study · recruiting
NCT06167343 — Comparison of Semitendinosus and Quadriceps Grafts for Anterior Cruciate Ligament Reconstruction · NA · active not recruiting
NCT03462823 — Use of an Osteoconductive Scaffold in ACL-Reconstruction · NA · active not recruiting

Other Rothman Institute Orthopaedics trials

Trials by the same sponsor.

NCT06903767 — Automated V Manual Impactor Study · NA · enrolling by invitation
NCT06601803 — Surgiphor Us in TSA · Phase 4 · enrolling by invitation
NCT06575010 — Exparel v Dexamethasone in RCR · Phase 4 · enrolling by invitation
NCT06536842 — Wound Drain After Lumbar Fusion Surgery · NA · enrolling by invitation
NCT06484192 — Pain Control After Lumbar Spine Fusion · Phase 4 · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06006624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rothman Institute Orthopaedics
Last refreshed: 21 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06006624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing